N/A N=21 Minds and Mentors Program (MiMP)- R61
Opioid-use Disorder · Medication Assisted Treatment · Substance Use Disorders
Primary: Number of Days Adherence to Medication Assisted Treatment — 28; 23.25 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Prostate Cancer · Prostate Neoplasms · Neoplasms, Prostatic
Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale
Phase 2 N=25 Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Gastroparesis
Primary: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate — 267.12; 283.09; 221.74 kPCD/minutes — p=<0.05
Phase 3 N=210 Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Type 1 Diabetes Mellitus
Primary: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following…
Phase 2 N=32 Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
Small Cell Lung Cancer (SCLC)
Primary: Overall Response Rate — 0; 9; 16; 7 Participants
N/A N=176 Mindful Movement for Physical Activity and Wellbeing in Older Adults- A Hybrid Effectiveness-Implementation Study
Physical Inactivty · Wellbeing · Mindfulness
Primary: Moderate-Vigorous Physical Activity (MVPA) in 10 Min Bouts — 18.35; 15.54 minutes per week
N/A N=98 SexHealth Mobile: Integrating a Mobile Clinic and a Point-of-care Contraception Counseling and Access
Contraceptive Usage · Contraception
Primary: Current Use of Highly Effective Contraception — 2; 17 Participants
Phase 1 N=8 Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
Alzheimer Disease
Primary: Plasma CT1812 Concentration at 96 Hours Timepoint — 0.0000707 μg/mL
N/A N=38 Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and Their Caregivers
Pathologic Processes
Primary: Number of Patients for Whom the Intervention Components Were Feasible — 16; 19; 15; 16 Participants
Phase 2 N=88 A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
Sickle Cell Disease
Primary: Double-Blind Treatment: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 6; 5; 5 Participants
Phase 4 N=304 Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients
Postoperative Pain
Primary: Morphine Milligram Equivalents (MME) of Oxycodone Tablets Taken by Patient — 1089.7; 777.1 Morphine Milligram Equivalents (MME)
N/A N=57 Silver Diamine Fluoride and Papain-Based Gel for Management of MIH-affected Molar in Paediatric Patients
Molar Incisor Hypomineralization · Dental Caries · Hypomineralization of Enamel
Primary: Clinical Outcome Based on Success After Intervention on MIH Affected Molar at 6 Months — 17; 18; 17 number of Successful MIH affected molars
N/A N=200 Vale+ Tu Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19
COVID-19
Primary: Number of Participants With Change in COVID-19 Vaccination Status Assessed by a Survey — 24; 36; 1; 0 Participants
Phase 2 N=106 Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
Irritable Mood · Huntington's Disease
Primary: Tolerability of SRX246 — 25; 27; 30 Participants
N/A N=55 Moderate-Intensity Exercise Versus High-Intensity Interval Training to Recover Walking Post-Stroke
Stroke
Primary: Six-Minute Walk Test Distance — 27; 12 meters